NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

NCT05569811 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Patritumab deruxtecan
DRUG: Chemotherapy
DRUG: Letrozole

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]